

AMENDMENTS TO LB1355

Introduced by Bosn, 25.

1           1. Insert the following new sections:

2           Section 1. Section 28-405, Revised Statutes Supplement, 2023, is  
3 amended to read:

4           28-405 The following are the schedules of controlled substances  
5 referred to in the Uniform Controlled Substances Act, unless specifically  
6 contained on the list of exempted products of the Drug Enforcement  
7 Administration of the United States Department of Justice as the list  
8 existed on January 31, 2022:

9           Schedule I

10          (a) Any of the following opiates, including their isomers, esters,  
11 ethers, salts, and salts of isomers, esters, and ethers, unless  
12 specifically excepted, whenever the existence of such isomers, esters,  
13 ethers, and salts is possible within the specific chemical designation:

14           (1) Acetylmethadol;

15           (2) Allylprodine;

16           (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also  
17 known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;

18           (4) Alphameprodine;

19           (5) Alphamethadol;

20           (6) Benzethidine;

21           (7) Betacetylmethadol;

22           (8) Betameprodine;

23           (9) Betamethadol;

24           (10) Betaprodine;

25           (11) Clonitazene;

26           (12) Dextromoramide;

27           (13) Difenoquin;

- 1 (14) Diampromide;
- 2 (15) Diethylthiambutene;
- 3 (16) Dimenoxadol;
- 4 (17) Dimepheptanol;
- 5 (18) Dimethylthiambutene;
- 6 (19) Dioxaphetyl butyrate;
- 7 (20) Dipipanone;
- 8 (21) Ethylmethylthiambutene;
- 9 (22) Etonitazene;
- 10 (23) Etoxeridine;
- 11 (24) Furethidine;
- 12 (25) Hydroxypethidine;
- 13 (26) Ketobemidone;
- 14 (27) Levomoramide;
- 15 (28) Levophenacymorphan;
- 16 (29) Morpheridine;
- 17 (30) Noracymethadol;
- 18 (31) Norlevorphanol;
- 19 (32) Normethadone;
- 20 (33) Norpipanone;
- 21 (34) Phenadoxone;
- 22 (35) Phenampromide;
- 23 (36) Phenomorphan;
- 24 (37) Phenoperidine;
- 25 (38) Piritramide;
- 26 (39) Proheptazine;
- 27 (40) Properidine;
- 28 (41) Propiram;
- 29 (42) Racemoramide;
- 30 (43) Trimeperidine;
- 31 (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl)-4-

- 1 piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)  
2 piperidine;  
3 (45) Tilidine;  
4 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-  
5 phenylpropanamide, its optical and geometric isomers, salts, and salts of  
6 isomers;  
7 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical  
8 isomers, salts, and salts of isomers;  
9 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its  
10 optical isomers, salts, and salts of isomers;  
11 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-  
12 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of  
13 isomers;  
14 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-  
15 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts  
16 of isomers;  
17 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,  
18 its optical isomers, salts, and salts of isomers;  
19 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-  
20 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts  
21 of isomers;  
22 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-  
23 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and  
24 geometric isomers, salts, and salts of isomers;  
25 (54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-  
26 piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,  
27 salts, and salts of isomers;  
28 (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide  
29 (thenylfentanyl), its optical isomers, salts, and salts of isomers;  
30 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-  
31 propanamide, its optical isomers, salts, and salts of isomers;

- 1 (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-
- 2 piperidinyl)propanamide, its optical isomers, salts, and salts of
- 3 isomers;
- 4 (58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
- 5 methylbenzamide;
- 6 (59) 4-Fluoroisobutyryl Fentanyl;
- 7 (60) Acetyl Fentanyl;
- 8 (61) Acyrloylfentanyl;
- 9 (62) AH-7921; 3, 4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]
- 10 benzamide;
- 11 (63) Butyryl fentanyl;
- 12 (64) Cyclopentyl fentanyl;
- 13 (65) Cyclopropyl fentanyl;
- 14 (66) Furanyl fentanyl;
- 15 (67) Isobutyryl fentanyl;
- 16 (68) Isotonitazene;
- 17 (69) Methoxyacetyl fentanyl;
- 18 (70) MT-45; 1-cyclohexyl-4-(1,2-diphenylethyl) piperazine;
- 19 (71) Tetrahydrofuranyl fentanyl;
- 20 (72) 2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-
- 21 yl) propionamide;
- 22 (73) Ocfentanil;
- 23 (74) Ortho-Fluorofentanyl;
- 24 (75) Para-chloroisobutyryl fentanyl;
- 25 (76) Para-Fluorobutyryl Fentanyl;
- 26 (77) Valeryl fentanyl;
- 27 (78) Phenyl Fentanyl;
- 28 (79) Para-Methylfentanyl;
- 29 (80) Thiofuranyl Fentanyl;
- 30 (81) Beta-methyl Fentanyl;
- 31 (82) Beta'-Phenyl Fentanyl;

- 1 (83) Crotonyl Fentanyl;
- 2 (84) 2'-Fluoro Ortho-Fluorofentanyl;
- 3 (85) 4'-Methyl Acetyl Fentanyl;
- 4 (86) Ortho-Fluorobutyryl Fentanyl;
- 5 (87) Ortho-Methyl Acetylfentanyl;
- 6 (88) Ortho-Methyl Methoxyacetyl Fentanyl;
- 7 (89) Ortho-Fluoroacryl Fentanyl;
- 8 (90) Fentanyl Carbamate;
- 9 (91) Ortho-Fluoroisobutyryl Fentanyl;
- 10 (92) Para-Fluoro Furanyl Fentanyl;
- 11 (93) Para-Methoxybutyryl Fentanyl;
- 12 (94) Brorphine (other name: 1-(1-(1-(4-bromophenyl) ethyl)
- 13 piperidin-4-yl-1,3-dihydro-2H-benzo[D]imidazole-2-one);~~and~~
- 14 (95) Fentanyl-related substances, their isomers, esters, ethers,
- 15 salts and salts of isomers, esters, and ethers. Unless specifically
- 16 excepted, listed in another schedule, or specifically named in this
- 17 schedule, this includes any substance that is structurally related to
- 18 fentanyl by one or more of the following modifications:
- 19 (A) Replacement of the phenyl portion of the phenethyl group by any
- 20 monocycle, whether or not further substituted in or on the monocycle;
- 21 (B) Substitution in or on the phenethyl group with alkyl, alkenyl,
- 22 alkoxy, hydroxyl, halo, haloalkyl, amino, or nitro groups;
- 23 (C) Substitution in or on the piperidine ring with alkyl, alkenyl,
- 24 alkoxy, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups;
- 25 (D) Replacement of the aniline ring with any aromatic monocycle
- 26 whether or not further substituted in or on the aromatic monocycle; or
- 27 (E) Replacement of the N-propionyl group by another acyl group;
- 28 and -
- 29 (96) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-
- 30 benzimidazol-1-yl)ethan-1-amine).
- 31 (b) Any of the following opium derivatives, their salts, isomers,

1 and salts of isomers, unless specifically excepted, whenever the  
2 existence of such salts, isomers, and salts of isomers is possible within  
3 the specific chemical designation:

- 4 (1) Acetorphine;
- 5 (2) Acetyldihydrocodeine;
- 6 (3) Benzylmorphine;
- 7 (4) Codeine methylbromide;
- 8 (5) Codeine-N-Oxide;
- 9 (6) Cyrenorphine;
- 10 (7) Desomorphine;
- 11 (8) Dihydromorphine;
- 12 (9) Drotebanol;
- 13 (10) Etorphine, except hydrochloride salt;
- 14 (11) Heroin;
- 15 (12) Hydromorphinol;
- 16 (13) Methyldesorphine;
- 17 (14) Methyldihydromorphine;
- 18 (15) Morphine methylbromide;
- 19 (16) Morphine methylsulfonate;
- 20 (17) Morphine-N-Oxide;
- 21 (18) Myrophine;
- 22 (19) Nicocodeine;
- 23 (20) Nicomorphine;
- 24 (21) Normorphine;
- 25 (22) Pholcodine; and
- 26 (23) Thebacon.

27 (c) Any material, compound, mixture, or preparation which contains  
28 any quantity of the following hallucinogenic substances, their salts,  
29 isomers, and salts of isomers, unless specifically excepted, whenever the  
30 existence of such salts, isomers, and salts of isomers is possible within  
31 the specific chemical designation, and, for purposes of this subdivision

1 only, isomer shall include the optical, position, and geometric isomers:

2 (1) Bufotenine. Trade and other names shall include, but are not  
3 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-  
4 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-  
5 dimethyltryptamine; and mappine;

6 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall  
7 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-  
8 methylphenethylamine; and 4-bromo-2,5-DMA;

9 (3) 4-methoxyamphetamine. Trade and other names shall include, but  
10 are not limited to: 4-methoxy-alpha-methylphenethylamine; and  
11 paramethoxyamphetamine, PMA;

12 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall  
13 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-  
14 methylphenethylamine; DOM; and STP;

15 (5) Para-methoxymethamphetamine. Trade and other names shall  
16 include, but are not limited to: 1-(4-Methoxyphenyl)-N-methylpropan-2-  
17 amine, PMMA, and 4-MMA;

18 (6) Ibogaine. Trade and other names shall include, but are not  
19 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-  
20 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe  
21 iboga;

22 (7) Lysergic acid diethylamide;

23 (8) Marijuana;

24 (9) Mescaline;

25 (10) Methoxetamine (MXE);

26 (11) Peyote. Peyote shall mean all parts of the plant presently  
27 classified botanically as *Lophophora williamsii* Lemaire, whether growing  
28 or not, the seeds thereof, any extract from any part of such plant, and  
29 every compound, manufacture, salts, derivative, mixture, or preparation  
30 of such plant or its seeds or extracts;

31 (12) Psilocybin;

1 (13) Psilocyn;

2 (14) Tetrahydrocannabinols, including, but not limited to, synthetic  
3 equivalents of the substances contained in the plant or in the resinous  
4 extractives of cannabis, sp. or synthetic substances, derivatives, and  
5 their isomers with similar chemical structure and pharmacological  
6 activity such as the following: Delta 1 cis or trans tetrahydrocannabinol  
7 and their optical isomers, excluding dronabinol in a drug product  
8 approved by the federal Food and Drug Administration; Delta 6 cis or  
9 trans tetrahydrocannabinol and their optical isomers; and Delta 3,4 cis  
10 or trans tetrahydrocannabinol and its optical isomers. Since nomenclature  
11 of these substances is not internationally standardized, compounds of  
12 these structures shall be included regardless of the numerical  
13 designation of atomic positions covered. Tetrahydrocannabinols does not  
14 include cannabidiol contained in a drug product approved by the federal  
15 Food and Drug Administration;

16 (15) N-ethyl-3-piperidyl benzilate;

17 (16) N-methyl-3-piperidyl benzilate;

18 (17) Thiophene analog of phencyclidine. Trade and other names shall  
19 include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine;  
20 2-thienyl analog of phencyclidine; TCP; and TCP;

21 (18) Hashish or concentrated cannabis;

22 (19) Parahexyl. Trade and other names shall include, but are not  
23 limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-  
24 dibenzo(b,d)pyran; and Synhexyl;

25 (20) Ethylamine analog of phencyclidine. Trade and other names shall  
26 include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-  
27 phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;  
28 cyclohexamine; and PCE;

29 (21) Pyrrolidine analog of phencyclidine. Trade and other names  
30 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-  
31 pyrrolidine; PCPy; and PHP;



1 (22) Alpha-ethyltryptamine. Some trade or other names: etryptamine;  
2 Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;  
3 alpha-ET; and AET;

4 (23) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;

5 (24) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;

6 (25) Alpha-methyltryptamine, which is also known as AMT;

7 (26) Salvia divinorum or Salvinorin A. Salvia divinorum or  
8 Salvinorin A includes all parts of the plant presently classified  
9 botanically as Salvia divinorum, whether growing or not, the seeds  
10 thereof, any extract from any part of such plant, and every compound,  
11 manufacture, derivative, mixture, or preparation of such plant, its  
12 seeds, or its extracts, including salts, isomers, and salts of isomers  
13 whenever the existence of such salts, isomers, and salts of isomers is  
14 possible within the specific chemical designation;

15 (27) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one (other  
16 names: eutylone or bk-EBDB);

17 (28) (27) Any material, compound, mixture, or preparation containing  
18 any quantity of synthetically produced cannabinoids as listed in  
19 subdivisions (A) through (L) of this subdivision, including their salts,  
20 isomers, salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic  
21 analogs, unless specifically excepted elsewhere in this section. Since  
22 nomenclature of these synthetically produced cannabinoids is not  
23 internationally standardized and may continually evolve, these structures  
24 or compounds of these structures shall be included under this  
25 subdivision, regardless of their specific numerical designation of atomic  
26 positions covered, so long as it can be determined through a recognized  
27 method of scientific testing or analysis that the substance contains  
28 properties that fit within one or more of the following categories:

29 (A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally  
30 contained in a plant of the genus cannabis (cannabis plant), as well as  
31 synthetic equivalents of the substances contained in the plant, or in the

1 resinous extractives of cannabis, sp. and/or synthetic substances,  
2 derivatives, and their isomers with similar chemical structure and  
3 pharmacological activity such as the following: Delta 1 cis or trans  
4 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans  
5 tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans  
6 tetrahydrocannabinol, and its optical isomers. This subdivision does not  
7 include cannabidiol contained in a drug product approved by the federal  
8 Food and Drug Administration;

9 (B) Naphthoylindoles: Any compound containing a 3-(1-  
10 naphthoyl)indole structure with substitution at the nitrogen atom of the  
11 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
12 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
13 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
14 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
15 tetrahydropyranylmethyl group, whether or not further substituted in or  
16 on any of the listed ring systems to any extent;

17 (C) Naphthylmethylinindoles: Any compound containing a 1 H-indol-3-  
18 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom  
19 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
20 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
21 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
22 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
23 tetrahydropyranylmethyl group, whether or not further substituted in or  
24 on any of the listed ring systems to any extent;

25 (D) Naphthoylpyrroles: Any compound containing a 3-(1-  
26 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the  
27 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
28 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
29 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
30 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
31 tetrahydropyranylmethyl group, whether or not further substituted in or

1 on any of the listed ring systems to any extent;

2 (E) Naphthylideneindenes: Any compound containing a  
3 naphthylideneindene structure with substitution at the 3-position of the  
4 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
5 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
6 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
7 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
8 tetrahydropyranylmethyl group, whether or not further substituted in or  
9 on any of the listed ring systems to any extent;

10 (F) Phenylacetylindoles: Any compound containing a 3-  
11 phenylacetylindole structure with substitution at the nitrogen atom of  
12 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
13 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
14 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
15 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
16 tetrahydropyranylmethyl group, whether or not further substituted in or  
17 on any of the listed ring systems to any extent;

18 (G) Cyclohexylphenols: Any compound containing a 2-(3-  
19 hydroxycyclohexyl)phenol structure with substitution at the 5-position of  
20 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,  
21 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,  
22 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-  
23 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
24 tetrahydropyranylmethyl group, whether or not substituted in or on any of  
25 the listed ring systems to any extent;

26 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole  
27 structure with substitution at the nitrogen atom of the indole ring by an  
28 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,  
29 cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-  
30 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
31 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not

1 further substituted in or on any of the listed ring systems to any  
2 extent;

3 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole  
4 structure with substitution at the nitrogen atom of the indole ring by an  
5 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,  
6 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,  
7 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
8 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not  
9 further substituted in or on any of the listed ring systems to any  
10 extent;

11 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-  
12 tetramethylcyclopropanoylindole structure with substitution at the  
13 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,  
14 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-  
15 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-  
16 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
17 tetrahydropyranylmethyl group, whether or not further substituted in or  
18 on any of the listed ring systems to any extent;

19 (K) Indole carboxamides: Any compound containing a 1-indole-3-  
20 carboxamide structure with substitution at the nitrogen atom of the  
21 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,  
22 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
23 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-  
24 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
25 tetrahydropyranylmethyl group, substitution at the carboxamide group by  
26 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,  
27 phenyl, aminoalkyl group, or quinolinyl group, whether or not further  
28 substituted in or on any of the listed ring systems to any extent or to  
29 the adamantyl, 1-naphthyl, phenyl, aminoalkyl, benzyl, or  
30 propionaldehyde groups to any extent;

31 (L) Indole carboxylates: Any compound containing a 1-indole-3-

1 carboxylate structure with substitution at the nitrogen atom of the  
2 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,  
3 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
4 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-  
5 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or  
6 tetrahydropyranylmethyl group, substitution at the carboxylate group by  
7 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,  
8 phenyl, aminoalkyl group, or quinolinyl group, whether or not further  
9 substituted in or on any of the listed ring systems to any extent or to  
10 the adamantyl, 1-naphthyl, phenyl, aminoalkyl, benzyl, or  
11 propionaldehyde groups to any extent; and

12 (M) Any nonnaturally occurring substance, chemical compound,  
13 mixture, or preparation, not specifically listed elsewhere in these  
14 schedules and which is not approved for human consumption by the federal  
15 Food and Drug Administration, containing or constituting a cannabinoid  
16 receptor agonist as defined in section 28-401;

17 (29) (28) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-  
18 phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol, including its isomers,  
19 esters, ethers, salts, and salts of isomers, esters, and ethers, whenever  
20 the existence of such isomers, esters, ethers, and salts is possible  
21 within the specific chemical designation;

22 (30) (29) Any material, compound, mixture, or preparation containing  
23 any quantity of a substituted phenethylamine as listed in subdivisions  
24 (A) through (C) of this subdivision, unless specifically excepted, listed  
25 in another schedule, or specifically named in this schedule, that is  
26 structurally derived from phenylethan-2-amine by substitution on the  
27 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a  
28 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by  
29 substitution with one alkoxy and either one fused furan, tetrahydrofuran,  
30 or tetrahydropyran ring system; or by substitution with two fused ring  
31 systems from any combination of the furan, tetrahydrofuran, or

1 tetrahydropyran ring systems, whether or not the compound is further  
2 modified in any of the following ways:

3 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,  
4 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-  
5 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen  
6 atom with alkyl, dialkyl, benzyl, hydroxybenzyl, or methoxybenzyl groups,  
7 and including, but not limited to:

8 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known  
9 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;

10 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known  
11 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;

12 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known  
13 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;

14 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H  
15 or 2,5-Dimethoxyphenethylamine;

16 (v) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine, which is also known as  
17 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;

18 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known  
19 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;

20 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also  
21 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;

22 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is  
23 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;

24 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is  
25 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;

26 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known  
27 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;

28 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also  
29 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;

30 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also  
31 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;

- 1 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also  
2 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
- 3 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also  
4 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
- 5 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-  
6 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-  
7 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
- 8 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-  
9 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-  
10 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
- 11 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,  
12 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-  
13 methoxybenzyl)phenethylamine;
- 14 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-  
15 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or  
16 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
- 17 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,  
18 which is also known as 2CB-5-hemiFLY;
- 19 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-  
20 yl)ethanamine, which is also known as 2C-B-FLY;
- 21 (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-  
22 yl)ethanamine, which is also known as 2C-B-butterFLY;
- 23 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-  
24 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-  
25 NBOMe;
- 26 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,  
27 which is also known as bromo-benzodifuranylisopropylamine or bromo-  
28 dragonFLY;
- 29 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which  
30 is also known as 2C-INBOH or 25I-NBOH;
- 31 (xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB;

1 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;  
2 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known  
3 as 5-APDB;  
4 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also  
5 known as 6-APDB;  
6 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-  
7 dimethoxy-a-methylphenethylamine; 2, 5-DMA;  
8 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;  
9 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also  
10 known as 2C-T-7;  
11 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;  
12 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as  
13 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;  
14 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;  
15 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as  
16 MDMA;  
17 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known  
18 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;  
19 (xxxvii) 3,4,5-trimethoxy amphetamine; and  
20 (xxxviii) n-hydroxy-3, 4-Methylenedioxy-N-Hydroxyamphetamine, which  
21 is also known as N-hydroxyMDA;  
22 (31) ~~(30)~~ Any material, compound, mixture, or preparation containing  
23 any quantity of a substituted tryptamine unless specifically excepted,  
24 listed in another schedule, or specifically named in this schedule, that  
25 is structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also  
26 known as tryptamine, by mono- or di-substitution of the amine nitrogen  
27 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom  
28 in a cyclic structure whether or not the compound is further substituted  
29 at the alpha position with an alkyl group or whether or not further  
30 substituted on the indole ring to any extent with any alkyl, alkoxy,  
31 halo, hydroxyl, or acetoxy groups, and including, but not limited to:



1 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-  
2 DALT;

3 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-  
4 DMT or OAcetylpsilocin;

5 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-  
6 HO-MET;

7 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-  
8 HO-DIPT;

9 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as  
10 5-MeOMiPT;

11 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-  
12 DMT;

13 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-  
14 MeO-DiPT;

15 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,  
16 DET; and

17 (I) Dimethyltryptamine, which is also known as DMT; and

18 (32)(A) ~~(31)(A)~~ Any substance containing any quantity of the  
19 following materials, compounds, mixtures, or structures:

20 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;

21 (ii) 3,4-methylenedioxypyrovalerone, or MDPV;

22 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;

23 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;

24 (v) Fluoromethcathinone, or FMC;

25 (vi) Naphthylpyrovalerone, or naphyrone; or

26 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or  
27 butylone; or

28 (B) Unless listed in another schedule, any substance which contains  
29 any quantity of any material, compound, mixture, or structure, other than  
30 bupropion, that is structurally derived by any means from 2-  
31 aminopropan-1-one by substitution at the 1-position with either phenyl,

1 naphthyl, or thiophene ring systems, whether or not the compound is  
2 further modified in any of the following ways:

3 (i) Substitution in the ring system to any extent with alkyl,  
4 alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents,  
5 whether or not further substituted in the ring system by one or more  
6 other univalent substituents;

7 (ii) Substitution at the 3-position with an acyclic alkyl  
8 substituent; or

9 (iii) Substitution at the 2-amino nitrogen atom with alkyl or  
10 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic  
11 structure.

12 (d) Unless specifically excepted or unless listed in another  
13 schedule, any material, compound, mixture, or preparation which contains  
14 any quantity of the following substances having a depressant effect on  
15 the central nervous system, including its salts, isomers, and salts of  
16 isomers whenever the existence of such salts, isomers, and salts of  
17 isomers is possible within the specific chemical designation:

18 (1) Amineptine 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-  
19 yl)amino]heptanoic acid, including its salts, isomers, and salts of  
20 isomers;

21 (2) Mecloqualone;

22 (3) Methaqualone; and

23 (4) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-  
24 hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium  
25 Oxybate; and Sodium Oxybutyrate.

26 (e) Unless specifically excepted or unless listed in another  
27 schedule, any material, compound, mixture, or preparation which contains  
28 any quantity of the following substances having a stimulant effect on the  
29 central nervous system, including its salts, isomers, and salts of  
30 isomers:

31 (1) Fenethylamine;

- 1 (2) N-ethylamphetamine;
- 2 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-  
3 dihydro-5-phenyl-2-oxazolamine;
- 4 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-  
5 aminopropiophenone; 2-aminopropiophenone; and norephedrone;
- 6 (5) Methcathinone, its salts, optical isomers, and salts of optical  
7 isomers. Some other names: 2-(methylamino)-propiophenone; alpha-  
8 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-  
9 N-methylaminopropiophenone; methylcathinone; monomethylpropion;  
10 ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; UR1432; and 4-MEC;
- 11 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-  
12 phenyl-2-oxazolamine;
- 13 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;  
14 and N,N-alpha-trimethylphenethylamine;
- 15 (8) Benzylpiperazine, 1-benzylpiperazine;
- 16 (9) 4,4'-dimethylaminorex (other names: 4,4'-DMAR, 4,5-dihydro-4-  
17 methyl-5-(4-methylphenyl)-2-oxazolamine); ~~and~~
- 18 (10) N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-  
19 ium-5-yl)carbamimidate), including its salts, isomers, and salts of  
20 isomers; ~~and~~
- 21 (11) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-  
22 oxadiazol-3-ium-5-yl)carbamimidate); and
- 23 (12) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine).
- 24 (f) Any controlled substance analogue to the extent intended for  
25 human consumption.
- 26 Schedule II
- 27 (a) Any of the following substances except those narcotic drugs  
28 listed in other schedules whether produced directly or indirectly by  
29 extraction from substances of vegetable origin, independently by means of  
30 chemical synthesis, or by combination of extraction and chemical  
31 synthesis:

1 (1) Opium and opiate, and any salt, compound, derivative, or  
2 preparation of opium or opiate, excluding apomorphine, buprenorphine,  
3 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmeferene,  
4 naloxone, and naltrexone and their salts, but including the following:

- 5 (A) Raw opium;
- 6 (B) Opium extracts;
- 7 (C) Opium fluid;
- 8 (D) Powdered opium;
- 9 (E) Granulated opium;
- 10 (F) Tincture of opium;
- 11 (G) Codeine;
- 12 (H) Ethylmorphine;
- 13 (I) Etorphine hydrochloride;
- 14 (J) Hydrocodone;
- 15 (K) Hydromorphone;
- 16 (L) Metopon;
- 17 (M) Morphine;
- 18 (N) Oxycodone;
- 19 (O) Oxymorphone;
- 20 (P) Oripavine;
- 21 (Q) Thebaine; and
- 22 (R) Dihydroetorphine;

23 (2) Any salt, compound, derivative, or preparation thereof which is  
24 chemically equivalent to or identical with any of the substances referred  
25 to in subdivision (1) of this subdivision, except that these substances  
26 shall not include the isoquinoline alkaloids of opium;

27 (3) Opium poppy and poppy straw;

28 (4) Coca leaves and any salt, compound, derivative, or preparation  
29 of coca leaves, and any salt, compound, derivative, or preparation  
30 thereof which is chemically equivalent to or identical with any of these  
31 substances, including cocaine or ecgonine and its salts, optical isomers,

1 and salts of optical isomers, except that the substances shall not  
2 include decocainized coca leaves or extractions which do not contain  
3 cocaine or ecgonine; and

4 (5) Concentrate of poppy straw, the crude extract of poppy straw in  
5 either liquid, solid, or powder form which contains the phenanthrene  
6 alkaloids of the opium poppy.

7 (b) Unless specifically excepted or unless in another schedule any  
8 of the following opiates, including their isomers, esters, ethers, salts,  
9 and salts of their isomers, esters, and ethers whenever the existence of  
10 such isomers, esters, ethers, and salts is possible within the specific  
11 chemical designation, dextrorphan excepted:

12 (1) Alphaprodine;

13 (2) Anileridine;

14 (3) Bezitramide;

15 (4) Diphenoxylate;

16 (5) Fentanyl;

17 (6) Isomethadone;

18 (7) Levomethorphan;

19 (8) Levorphanol;

20 (9) Metazocine;

21 (10) Methadone;

22 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl  
23 butane;

24 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-  
25 diphenylpropane-carboxylic acid;

26 (13) Norfentanyl (N-phenyl-N-piperidin-4-yl) propionamide;

27 (14) Oliceridine;

28 (15) Pethidine or meperidine;

29 (16) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;

30 (17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-  
31 carboxylate;

- 1 (18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
  - 2 carboxylic acid;
  - 3 (19) Phenazocine;
  - 4 (20) Piminodine;
  - 5 (21) Racemethorphan;
  - 6 (22) Racemorphan;
  - 7 (23) Dihydrocodeine;
  - 8 (24) Bulk Propoxyphene in nondosage forms;
  - 9 (25) Sufentanil;
  - 10 (26) Alfentanil;
  - 11 (27) Levo-alphaacetylmethadol which is also known as levo-alpha-
  - 12 acetylmethadol, levomethadyl acetate, and LAAM;
  - 13 (28) Carfentanil;
  - 14 (29) Remifentanil;
  - 15 (30) Tapentadol; and
  - 16 (31) Thiafentanil.
- 17 (c) Any material, compound, mixture, or preparation which contains
- 18 any quantity of the following substances having a potential for abuse
- 19 associated with a stimulant effect on the central nervous system:
- 20 (1) Amphetamine, its salts, optical isomers, and salts of its
  - 21 optical isomers;
  - 22 (2) Phenmetrazine and its salts;
  - 23 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
  - 24 (4) Methylphenidate; and
  - 25 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.
- 26 (d) Any material, compound, mixture, or preparation which contains
- 27 any quantity of the following substances having a potential for abuse
- 28 associated with a depressant effect on the central nervous system,
- 29 including their salts, isomers, and salts of isomers whenever the
- 30 existence of such salts, isomers, and salts of isomers is possible within
- 31 the specific chemical designations:

- 1 (1) Amobarbital;
- 2 (2) Secobarbital;
- 3 (3) Pentobarbital;
- 4 (4) Phencyclidine; and
- 5 (5) Glutethimide.

6 (e) Hallucinogenic substances known as:

7 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-  
8 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-  
9 dibenzo(b,d)pyran-9-one; and

10 (2) Dronabinol in an oral solution in a drug product approved by the  
11 federal Food and Drug Administration.

12 (f) Unless specifically excepted or unless listed in another  
13 schedule, any material, compound, mixture, or preparation which contains  
14 any quantity of the following substances:

15 (1) Immediate precursor to amphetamine and methamphetamine:  
16 Phenylacetone. Trade and other names shall include, but are not limited  
17 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl  
18 ketone;

19 (2) Immediate precursors to phencyclidine, PCP:

20 (A) 1-phenylcyclohexylamine; or

21 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or

22 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethylpiperidine  
23 (ANPP).

24 Schedule III

25 (a) Any material, compound, mixture, or preparation which contains  
26 any quantity of the following substances having a potential for abuse  
27 associated with a stimulant effect on the central nervous system,  
28 including their salts, isomers, whether optical, position, or geometric,  
29 and salts of such isomers whenever the existence of such salts, isomers,  
30 and salts of isomers is possible within the specific chemical  
31 designation:

- 1 (1) Benzphetamine;
- 2 (2) Chlorphentermine;
- 3 (3) Clortermine; and
- 4 (4) Phendimetrazine.

5 (b) Any material, compound, mixture, or preparation which contains  
6 any quantity of the following substances having a potential for abuse  
7 associated with a depressant effect on the central nervous system:

8 (1) Any substance which contains any quantity of a derivative of  
9 barbituric acid or any salt of a derivative of barbituric acid, except  
10 those substances which are specifically listed in other schedules of this  
11 section;

- 12 (2) Aprobarbital;
- 13 (3) Butabarbital;
- 14 (4) Butalbital;
- 15 (5) Butethal;
- 16 (6) Butobarbital;
- 17 (7) Chlorhexadol;
- 18 (8) Embutramide;
- 19 (9) Lysergic acid;
- 20 (10) Lysergic acid amide;
- 21 (11) Methyprylon;
- 22 (12) Perampanel;
- 23 (13) Secbutabarbital;
- 24 (14) Sulfondiethylmethane;
- 25 (15) Sulfonethylmethane;
- 26 (16) Sulfonmethane;
- 27 (17) Nalorphine;
- 28 (18) Talbutal;
- 29 (19) Thiamylal;
- 30 (20) Thiopental;
- 31 (21) Vinbarbital;



1 (22) Any compound, mixture, or preparation containing amobarbital,  
2 secobarbital, pentobarbital, or any salt thereof and one or more other  
3 active medicinal ingredients which are not listed in any schedule;

4 (23) Any suppository dosage form containing amobarbital,  
5 secobarbital, pentobarbital, or any salt of any of these drugs and  
6 approved by the federal Food and Drug Administration for marketing only  
7 as a suppository;

8 (24) Any drug product containing gamma-hydroxybutyric acid,  
9 including its salts, isomers, and salts of isomers, for which an  
10 application is approved under section 505 of the Federal Food, Drug, and  
11 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;

12 (25) Ketamine, its salts, isomers, and salts of isomers. Some other  
13 names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-  
14 cyclohexanone; ~~and~~

15 (26) Tiletamine and zolazepam or any salt thereof. Trade or other  
16 names for a tiletamine-zolazepam combination product shall include, but  
17 are not limited to: telazol. Trade or other names for tiletamine shall  
18 include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-  
19 cyclohexanone. Trade or other names for zolazepam shall include, but are  
20 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-  
21 trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrzapon;  
22 and -

23 (27)(A) Xylazine or any of the substances listed below, including  
24 their salts, isomers, and salts of isomers whenever the existence of such  
25 salts, isomers, and salts of isomers is possible within the specific  
26 chemical designation:

27 (i) Xylazine-M (2,6-dimethylaniline);

28 (ii) Xylazine-M (N-thiourea-2,6-dimethylaniline);

29 (iii) Xylazine-M (sulfone-HO-) isomer 2;

30 (iv) Xylazine-M (HO-2,6-dimethylaniline isomer 1);

31 (v) Xylazine-M (HO-2,6-dimethylaniline isomer 2);

- 1        (vi) Xylazine M (oxo-);
- 2        (vii) Xylazine-M (HO-) isomer 1;
- 3        (viii) Xylazine-M (HO-) isomer 1 glucuronide;
- 4        (ix) Xylazine-M (HO-) isomer 2;
- 5        (x) Xylazine-M (HO-) isomer 2 glucuronide;
- 6        (xi) Xylazine-M (HO-oxo-) isomer 1;
- 7        (xii) Xylazine-M (HO-oxo-) isomer 1 glucuronide;
- 8        (xiii) Xylazine-M (HO-oxo-) isomer 2;
- 9        (xiv) Xylazine-M (HO-oxo-) isomer 2 glucuronide;
- 10       (xv) Xylazine-M (sulfone); and
- 11       (xvi) Xylazine-M (sulfone-HO-) isomer 1.

12       (B) This subdivision (27) shall not include xylazine when it is used  
13 in any of the following manners:

14       (i) Dispensing or prescribing for, or administering to, a nonhuman  
15 species a drug containing xylazine that has been approved by the United  
16 States Secretary of Health and Human Services under section 512 of the  
17 Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 360b, as such act existed  
18 on January 1, 2024;

19       (ii) Dispensing or prescribing for, or administering to, a nonhuman  
20 species that is permissible under section 512(a)(4) of the Federal Food,  
21 Drug, and Cosmetic Act, 21 U.S.C. 360b(a)(4), as such act existed on  
22 January 1, 2024;

23       (iii) The manufacturing, distribution, or use of xylazine as an  
24 active pharmaceutical ingredient for manufacturing an animal drug that  
25 has been approved under section 512 of the Federal Food, Drug, and  
26 Cosmetic Act, 21 U.S.C. 360b, or that has been issued an investigational  
27 use exemption under section 512(j) of the act, 21 U.S.C. 360b(j), as such  
28 act existed on January 1, 2024;

29       (iv) The manufacturing, distribution, or use of a xylazine bulk  
30 chemical for pharmaceutical compounding by licensed pharmacists or  
31 veterinarians for a nonhuman species in accordance with subdivision (B)

1 (i) or (ii) of this subdivision (27); or  
2 (v) Any other use approved or permissible under the Federal Food,  
3 Drug, and Cosmetic Act, when dispensed or prescribed for, or administered  
4 to, a nonhuman species in accordance with subdivision (B)(i) or (ii) of  
5 this subdivision (27).

6 (c) Unless specifically excepted or unless listed in another  
7 schedule:

8 (1) Any material, compound, mixture, or preparation containing  
9 limited quantities of any of the following narcotic drugs, or any salts  
10 calculated as the free anhydrous base or alkaloid, in limited quantities  
11 as set forth below:

12 (A) Not more than one and eight-tenths grams of codeine per one  
13 hundred milliliters or not more than ninety milligrams per dosage unit,  
14 with an equal or greater quantity of an isoquinoline alkaloid of opium;

15 (B) Not more than one and eight-tenths grams of codeine per one  
16 hundred milliliters or not more than ninety milligrams per dosage unit,  
17 with one or more active, nonnarcotic ingredients in recognized  
18 therapeutic amounts;

19 (C) Not more than one and eight-tenths grams of dihydrocodeine per  
20 one hundred milliliters or not more than ninety milligrams per dosage  
21 unit, with one or more active, nonnarcotic ingredients in recognized  
22 therapeutic amounts;

23 (D) Not more than three hundred milligrams of ethylmorphine per one  
24 hundred milliliters or not more than fifteen milligrams per dosage unit,  
25 with one or more active, nonnarcotic ingredients in recognized  
26 therapeutic amounts;

27 (E) Not more than five hundred milligrams of opium per one hundred  
28 milliliters or per one hundred grams, or not more than twenty-five  
29 milligrams per dosage unit, with one or more active, nonnarcotic  
30 ingredients in recognized therapeutic amounts; and

31 (F) Not more than fifty milligrams of morphine per one hundred

1 milliliters or per one hundred grams with one or more active, nonnarcotic  
2 ingredients in recognized therapeutic amounts; and

3 (2) Any material, compound, mixture, or preparation containing any  
4 of the following narcotic drug or its salts, as set forth below:

5 (A) Buprenorphine.

6 (d) Unless contained on the list of exempt anabolic steroids of the  
7 Drug Enforcement Administration of the United States Department of  
8 Justice as the list existed on January 31, 2022, any anabolic steroid,  
9 which shall include any material, compound, mixture, or preparation  
10 containing any quantity of the following substances, including its salts,  
11 isomers, and salts of isomers whenever the existence of such salts of  
12 isomers is possible within the specific chemical designation:

13 (1) 3-beta,17-dihydroxy-5a-androstane;

14 (2) 3-alpha,17-beta-dihydroxy-5a-androstane;

15 (3) 5-alpha-androstan-3,17-dione;

16 (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-  
17 ene);

18 (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-  
19 ene);

20 (6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);

21 (7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);

22 (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);

23 (9) 4-androstenedione (androst-4-en-3,17-dione);

24 (10) 5-androstenedione (androst-5-en-3,17-dione);

25 (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-  
26 hydroxyandrost-4-en-3-one);

27 (12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);

28 (13) Boldione (androsta-1,4-diene-3,17-3-one);

29 (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-  
30 en-3-one);

31 (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);

- 1 (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-
- 2 alpha-methyl-androst-1,4-dien-3-one);
- 3 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-
- 4 en-17-beta-ol) (a.k.a. 'madol');
- 5 (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
- 6 hydroxy-5-alpha-androst-1-en-3-one);
- 7 (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
- 8 (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-
- 9 androstan-3-one);
- 10 (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
- 11 (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
- 12 dihydroxyandrost-4-en-3-one);
- 13 (23) Formebolone (formebolone); (2-formyl-17-alpha-methyl-11-
- 14 alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
- 15 (24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-
- 16 furazan);
- 17 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
- 18 (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);
- 19 (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-
- 20 one);
- 21 (28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
- 22 one);
- 23 (29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
- 24 one);
- 25 (30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-
- 26 dien-3-one);
- 27 (31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-
- 28 ene);
- 29 (32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-
- 30 beta-ol-3-one);
- 31 (33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-

- 1 one);
- 2 (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
- 3 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
- 4 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;
- 5 (37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-
- 6 hydroxy-17-beta-hydroxyestr-4-en-3-one);
- 7 (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-
- 8 dien-3-one);
- 9 (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-
- 10 trien-3-one);
- 11 (40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-
- 12 en-3-one);
- 13 (41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-
- 14 en-3-one);
- 15 (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-
- 16 hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-
- 17 methyl-1-testosterone');
- 18 (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);
- 19 (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
- 20 (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);
- 21 (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
- 22 (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
- 23 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-
- 24 dione);
- 25 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- 26 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 27 (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-
- 28 en-3-one);
- 29 (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);
- 30 (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-
- 31 one);

- 1 (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-  
2 one);
- 3 (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-  
4 androstan-3-one);
- 5 (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-  
6 en-3-one);
- 7 (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-  
8 hydroxy-[5-alpha]-androstan-3-one);
- 9 (58) Prostanazol (17-beta-hydroxy-5-alpha-androstano[3,2-  
10 c]pyrazole);
- 11 (59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-  
12 androst-2-eno[3,2-c]-pyrazole);
- 13 (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-  
14 one);
- 15 (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-  
16 oic acid lactone);
- 17 (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
- 18 (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-  
19 hydroxygon-4,9,11-trien-3-one);
- 20 (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one);
- 21 (65) [3,2-c]-furazan-5 alpha-androstane-17 beta-ol;
- 22 (66) [3,2-c]pyrazole-androst-4-en-17 beta-ol;
- 23 (67) 17 alpha-methyl-androst-ene-3,17 beta-diol;
- 24 (68) 17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
- 25 (69) 17 alpha-methyl-androstan-3-hydroxyimine-17 beta-ol;
- 26 (70) 17 beta-hydroxy-androstano[2,3-d]isoxazole;
- 27 (71) 17 beta-hydroxy-androstano[3,2-c]isoxazole;
- 28 (72) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
- 29 (73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17  
30 beta-ol;
- 31 (74) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3-one;

- 1 (75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-  
2 dione;
- 3 (76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;
- 4 (77) 4-chloro-17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
- 5 (78) 4-hydroxy-androst-4-ene-3,17-dione;
- 6 (79) 5 alpha-Androstan-3,6,17-trione;
- 7 (80) 6-bromo-androst-1,4-diene-3,17-dione;
- 8 (81) 6-bromo-androstan-3,17-dione;
- 9 (82) 6 alpha-methyl-androst-4-ene-3,17-dione;
- 10 (83) Delta 1-dihydrotestosterone;
- 11 (84) Estra-4,9,11-triene-3,17-dione; and
- 12 (85) Any salt, ester, or ether of a drug or substance described or  
13 listed in this subdivision if the salt, ester, or ether promotes muscle  
14 growth.

15 (e) Hallucinogenic substances known as:

16 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft  
17 gelatin capsule in a drug product approved by the federal Food and Drug  
18 Administration. Some other names for dronabinol are (6aR-  
19 trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo  
20 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.

21 Schedule IV

22 (a) Any material, compound, mixture, or preparation which contains  
23 any quantity of the following substances, including their salts, isomers,  
24 and salts of isomers whenever the existence of such salts, isomers, and  
25 salts of isomers is possible within the specific chemical designation:

- 26 (1) Barbital;
- 27 (2) Chloral betaine;
- 28 (3) Chloral hydrate;
- 29 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide  
30 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and  
31 water soluble esterified estrogens);



- 1 (5) Clonazepam;
- 2 (6) Clorazepate;
- 3 (7) Daridorexant;
- 4 (8) Diazepam;
- 5 (9) Ethchlorvynol;
- 6 (10) Ethinamate;
- 7 (11) Flurazepam;
- 8 (12) Mebutamate;
- 9 (13) Meprobamate;
- 10 (14) Methohexital;
- 11 (15) Methylphenobarbital;
- 12 (16) Oxazepam;
- 13 (17) Paraldehyde;
- 14 (18) Petrichloral;
- 15 (19) Phenobarbital;
- 16 (20) Prazepam;
- 17 (21) Alprazolam;
- 18 (22) Bromazepam;
- 19 (23) Camazepam;
- 20 (24) Clobazam;
- 21 (25) Clotiazepam;
- 22 (26) Cloxazolam;
- 23 (27) Delorazepam;
- 24 (28) Estazolam;
- 25 (29) Ethyl loflazepate;
- 26 (30) Fludiazepam;
- 27 (31) Flunitrazepam;
- 28 (32) Halazepam;
- 29 (33) Haloxazolam;
- 30 (34) Ketazolam;
- 31 (35) Loprazolam;

- 1 (36) Lorazepam;
- 2 (37) Lormetazepam;
- 3 (38) Medazepam;
- 4 (39) Nimetazepam;
- 5 (40) Nitrazepam;
- 6 (41) Nordiazepam;
- 7 (42) Oxazolam;
- 8 (43) Pinazepam;
- 9 (44) Temazepam;
- 10 (45) Tetrazepam;
- 11 (46) Triazolam;
- 12 (47) Midazolam;
- 13 (48) Quazepam;
- 14 (49) Zolpidem;
- 15 (50) Dichloralphenazone;
- 16 (51) Zaleplon;
- 17 (52) Zopiclone;
- 18 (53) Fospropofol;
- 19 (54) Alfaxalone;
- 20 (55) Suvorexant;
- 21 (56) Carisoprodol;
- 22 (57) Brexanolone; 3 alpha-hydroxy-5 alpha-pregnan-20-one;
- 23 (58) Lemborexant;
- 24 (59) Solriamfetol; 2-amino-3-phenylpropyl carbamate;
- 25 (60) Remimazolam; and
- 26 (61) Serdexmethylphenidate.
- 27 ~~(b) Any material, compound, mixture, or preparation which contains~~
- 28 ~~any quantity of the following substance, including its salts, isomers,~~
- 29 ~~whether optical, position, or geometric, and salts of such isomers,~~
- 30 ~~whenever the existence of such salts, isomers, and salts of isomers is~~
- 31 ~~possible: Fenfluramine.~~

1           **(b)** ~~(e)~~ Unless specifically excepted or unless listed in another  
2 schedule, any material, compound, mixture, or preparation which contains  
3 any quantity of the following substances having a stimulant effect on the  
4 central nervous system, including their salts, isomers, whether optical,  
5 position, or geometric, and salts of such isomers whenever the existence  
6 of such salts, isomers, and salts of isomers is possible within the  
7 specific chemical designation:

8           (1) Diethylpropion;

9           (2) Phentermine;

10          (3) Pemoline, including organometallic complexes and chelates  
11 thereof;

12          (4) Mazindol;

13          (5) Pipradrol;

14          (6) SPA, ((-)-1-dimethylamino-1,2-diphenylethane);

15          (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);

16          (8) Fencamfamin;

17          (9) Fenproporex;

18          (10) Mefenorex;

19          (11) Modafinil; and

20          (12) Sibutramine.

21           **(c)** ~~(d)~~ Unless specifically excepted or unless listed in another  
22 schedule, any material, compound, mixture, or preparation which contains  
23 any quantity of the following narcotic drugs, or their salts or isomers  
24 calculated as the free anhydrous base or alkaloid, in limited quantities  
25 as set forth below:

26          (1) Propoxyphene in manufactured dosage forms;

27          (2) Not more than one milligram of difenoxin and not less than  
28 twenty-five micrograms of atropine sulfate per dosage unit; and

29          (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its  
30 salts, optical and geometric isomers, and salts of these isomers to  
31 include: Tramadol.

1           ~~(d)~~ ~~(e)~~ Unless specifically excepted or unless listed in another  
2 schedule, any material, compound, mixture, or preparation which contains  
3 any quantity of the following substances ~~substance~~, including their ~~its~~  
4 salts:

5           (1) Pentazocine; and

6           (2) Butorphanol (including its optical isomers).

7           ~~(e)~~ ~~(f)~~ Any material, compound, mixture, or preparation which  
8 contains any quantity of the following substance ~~substances~~, including  
9 its salts, isomers, and salts of such isomers, whenever the existence of  
10 such salts, isomers, and salts of isomers is possible: Lorcaserin.

11           ~~(f)(1)~~ ~~(g)(1)~~ Unless specifically excepted or unless listed in  
12 another schedule, any material, compound, mixture, or preparation which  
13 contains any quantity of the following substance, including its salts,  
14 optical isomers, and salts of such optical isomers: Ephedrine.

15           (2) The following drug products containing ephedrine, its salts,  
16 optical isomers, and salts of such optical isomers, are excepted from  
17 subdivision ~~(f)(1)~~ ~~(g)(1)~~ of Schedule IV if they (A) are stored behind a  
18 counter, in an area not accessible to customers, or in a locked case so  
19 that a customer needs assistance from an employee to access the drug  
20 product; (B) are sold by a person, eighteen years of age or older, in the  
21 course of his or her employment to a customer eighteen years of age or  
22 older with the following restrictions: No customer shall be allowed to  
23 purchase, receive, or otherwise acquire more than three and six-tenths  
24 grams of ephedrine base during a twenty-four-hour period; no customer  
25 shall purchase, receive, or otherwise acquire more than nine grams of  
26 ephedrine base during a thirty-day period; and the customer shall display  
27 a valid driver's or operator's license, a Nebraska state identification  
28 card, a military identification card, an alien registration card, or a  
29 passport as proof of identification; (C) are labeled and marketed in a  
30 manner consistent with the pertinent OTC Tentative Final or Final  
31 Monograph; (D) are manufactured and distributed for legitimate medicinal

1 use in a manner that reduces or eliminates the likelihood of abuse; and  
2 (E) are not marketed, advertised, or represented in any manner for the  
3 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or  
4 high, heightened sexual performance, or increased muscle mass:

- 5 (i) Primatene Tablets; and
- 6 (ii) Bronkaid Dual Action Caplets.

7 Schedule V

8 (a) Any compound, mixture, or preparation containing any of the  
9 following limited quantities of narcotic drugs or salts calculated as the  
10 free anhydrous base or alkaloid, which shall include one or more  
11 nonnarcotic active medicinal ingredients in sufficient proportion to  
12 confer upon the compound, mixture, or preparation valuable medicinal  
13 qualities other than those possessed by the narcotic drug alone:

14 (1) Not more than two hundred milligrams of codeine per one hundred  
15 milliliters or per one hundred grams;

16 (2) Not more than one hundred milligrams of dihydrocodeine per one  
17 hundred milliliters or per one hundred grams;

18 (3) Not more than one hundred milligrams of ethylmorphine per one  
19 hundred milliliters or per one hundred grams;

20 (4) Not more than two and five-tenths milligrams of diphenoxylate  
21 and not less than twenty-five micrograms of atropine sulfate per dosage  
22 unit;

23 (5) Not more than one hundred milligrams of opium per one hundred  
24 milliliters or per one hundred grams; and

25 (6) Not more than five-tenths milligram of difenoxin and not less  
26 than twenty-five micrograms of atropine sulfate per dosage unit.

27 (b) Unless specifically exempted or excluded or unless listed in  
28 another schedule, any material, compound, mixture, or preparation which  
29 contains any quantity of the following substances having a stimulant  
30 effect on the central nervous system, including its salts, isomers, and  
31 salts of isomers: Pyrovalerone.

1 (c) Unless specifically exempted or excluded or unless listed in  
2 another schedule, any material, compound, mixture, or preparation which  
3 contains any quantity of the following substances having a depressant  
4 effect on the central nervous system, including its salts, isomers, and  
5 salts of isomers:

6 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic  
7 acid ethyl ester);

8 (2) Ganaxolone;

9 (3) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);

10 (4) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid);

11 (5) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]  
12 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its  
13 salts;

14 (6) Cenobamate; and

15 (7) Lasmiditan.

16 Sec. 2. Section 28-416, Revised Statutes Supplement, 2023, is  
17 amended to read:

18 28-416 (1) Except as authorized by the Uniform Controlled Substances  
19 Act, it shall be unlawful for any person knowingly or intentionally: (a)  
20 To manufacture, distribute, deliver, dispense, or possess with intent to  
21 manufacture, distribute, deliver, or dispense a controlled substance; or  
22 (b) to create, distribute, or possess with intent to distribute a  
23 counterfeit controlled substance.

24 (2) Except as provided in subsections (4), (5), (7), (8), (9), and  
25 (10) of this section, any person who violates subsection (1) of this  
26 section with respect to: (a) A controlled substance classified in  
27 Schedule I, II, or III of section 28-405 which is an exceptionally  
28 hazardous drug shall be guilty of a Class II felony; (b) any other  
29 controlled substance classified in Schedule I, II, or III of section  
30 28-405 shall be guilty of a Class IIA felony; or (c) a controlled  
31 substance classified in Schedule IV or V of section 28-405 shall be

1 guilty of a Class IIIA felony.

2 (3) A person knowingly or intentionally possessing a controlled  
3 substance, except marijuana or any substance containing a quantifiable  
4 amount of the substances, chemicals, or compounds described, defined, or  
5 delineated in subdivision (c)(28) ~~(e)(27)~~ of Schedule I of section  
6 28-405, unless such substance was obtained directly or pursuant to a  
7 medical order issued by a practitioner authorized to prescribe while  
8 acting in the course of his or her professional practice, or except as  
9 otherwise authorized by the act, shall be guilty of a Class IV felony. A  
10 person shall not be in violation of this subsection if section 28-472 or  
11 28-1701 applies.

12 (4)(a) Except as authorized by the Uniform Controlled Substances  
13 Act, any person eighteen years of age or older who knowingly or  
14 intentionally manufactures, distributes, delivers, dispenses, or  
15 possesses with intent to manufacture, distribute, deliver, or dispense a  
16 controlled substance or a counterfeit controlled substance (i) to a  
17 person under the age of eighteen years, (ii) in, on, or within one  
18 thousand feet of the real property comprising a public or private  
19 elementary, vocational, or secondary school, a community college, a  
20 public or private college, junior college, or university, or a  
21 playground, or (iii) within one hundred feet of a public or private youth  
22 center, public swimming pool, or video arcade facility shall be punished  
23 by the next higher penalty classification than the penalty prescribed in  
24 subsection (2), (7), (8), (9), or (10) of this section, depending upon  
25 the controlled substance involved, for the first violation and for a  
26 second or subsequent violation shall be punished by the next higher  
27 penalty classification than that prescribed for a first violation of this  
28 subsection, but in no event shall such person be punished by a penalty  
29 greater than a Class IB felony.

30 (b) For purposes of this subsection:

31 (i) Playground means any outdoor facility, including any parking lot

1 appurtenant to the facility, intended for recreation, open to the public,  
2 and with any portion containing three or more apparatus intended for the  
3 recreation of children, including sliding boards, swingsets, and  
4 teeterboards;

5 (ii) Video arcade facility means any facility legally accessible to  
6 persons under eighteen years of age, intended primarily for the use of  
7 pinball and video machines for amusement, and containing a minimum of ten  
8 pinball or video machines; and

9 (iii) Youth center means any recreational facility or gymnasium,  
10 including any parking lot appurtenant to the facility or gymnasium,  
11 intended primarily for use by persons under eighteen years of age which  
12 regularly provides athletic, civic, or cultural activities.

13 (5)(a) Except as authorized by the Uniform Controlled Substances  
14 Act, it shall be unlawful for any person eighteen years of age or older  
15 to knowingly and intentionally employ, hire, use, cause, persuade, coax,  
16 induce, entice, seduce, or coerce any person under the age of eighteen  
17 years to manufacture, transport, distribute, carry, deliver, dispense,  
18 prepare for delivery, offer for delivery, or possess with intent to do  
19 the same a controlled substance or a counterfeit controlled substance.

20 (b) Except as authorized by the Uniform Controlled Substances Act,  
21 it shall be unlawful for any person eighteen years of age or older to  
22 knowingly and intentionally employ, hire, use, cause, persuade, coax,  
23 induce, entice, seduce, or coerce any person under the age of eighteen  
24 years to aid and abet any person in the manufacture, transportation,  
25 distribution, carrying, delivery, dispensing, preparation for delivery,  
26 offering for delivery, or possession with intent to do the same of a  
27 controlled substance or a counterfeit controlled substance.

28 (c) Any person who violates subdivision (a) or (b) of this  
29 subsection shall be punished by the next higher penalty classification  
30 than the penalty prescribed in subsection (2), (7), (8), (9), or (10) of  
31 this section, depending upon the controlled substance involved, for the



1 first violation and for a second or subsequent violation shall be  
2 punished by the next higher penalty classification than that prescribed  
3 for a first violation of this subsection, but in no event shall such  
4 person be punished by a penalty greater than a Class IB felony.

5 (6) It shall not be a defense to prosecution for violation of  
6 subsection (4) or (5) of this section that the defendant did not know the  
7 age of the person through whom the defendant violated such subsection.

8 (7) Any person who violates subsection (1) of this section with  
9 respect to cocaine or any mixture or substance containing a detectable  
10 amount of cocaine in a quantity of:

11 (a) One hundred forty grams or more shall be guilty of a Class IB  
12 felony;

13 (b) At least twenty-eight grams but less than one hundred forty  
14 grams shall be guilty of a Class IC felony; or

15 (c) At least ten grams but less than twenty-eight grams shall be  
16 guilty of a Class ID felony.

17 (8) Any person who violates subsection (1) of this section with  
18 respect to base cocaine (crack) or any mixture or substance containing a  
19 detectable amount of base cocaine in a quantity of:

20 (a) One hundred forty grams or more shall be guilty of a Class IB  
21 felony;

22 (b) At least twenty-eight grams but less than one hundred forty  
23 grams shall be guilty of a Class IC felony; or

24 (c) At least ten grams but less than twenty-eight grams shall be  
25 guilty of a Class ID felony.

26 (9) Any person who violates subsection (1) of this section with  
27 respect to heroin or any mixture or substance containing a detectable  
28 amount of heroin in a quantity of:

29 (a) One hundred forty grams or more shall be guilty of a Class IB  
30 felony;

31 (b) At least twenty-eight grams but less than one hundred forty

1 grams shall be guilty of a Class IC felony; or

2 (c) At least ten grams but less than twenty-eight grams shall be  
3 guilty of a Class ID felony.

4 (10) Any person who violates subsection (1) of this section with  
5 respect to amphetamine, its salts, optical isomers, and salts of its  
6 isomers, or with respect to methamphetamine, its salts, optical isomers,  
7 and salts of its isomers, in a quantity of:

8 (a) One hundred forty grams or more shall be guilty of a Class IB  
9 felony;

10 (b) At least twenty-eight grams but less than one hundred forty  
11 grams shall be guilty of a Class IC felony; or

12 (c) At least ten grams but less than twenty-eight grams shall be  
13 guilty of a Class ID felony.

14 (11) Any person knowingly or intentionally possessing marijuana  
15 weighing more than one ounce but not more than one pound shall be guilty  
16 of a Class III misdemeanor.

17 (12) Any person knowingly or intentionally possessing marijuana  
18 weighing more than one pound shall be guilty of a Class IV felony.

19 (13) Except as provided in section 28-1701, any person knowingly or  
20 intentionally possessing marijuana weighing one ounce or less or any  
21 substance containing a quantifiable amount of the substances, chemicals,  
22 or compounds described, defined, or delineated in subdivision (c)(28) ~~(e)~~  
23 ~~(27)~~ of Schedule I of section 28-405 shall:

24 (a) For the first offense, be guilty of an infraction, receive a  
25 citation, be fined three hundred dollars, and be assigned to attend a  
26 course as prescribed in section 29-433 if the judge determines that  
27 attending such course is in the best interest of the individual  
28 defendant;

29 (b) For the second offense, be guilty of a Class IV misdemeanor,  
30 receive a citation, and be fined four hundred dollars and may be  
31 imprisoned not to exceed five days; and

1 (c) For the third and all subsequent offenses, be guilty of a Class  
2 IIIA misdemeanor, receive a citation, be fined five hundred dollars, and  
3 be imprisoned not to exceed seven days.

4 (14) Any person convicted of violating this section, if placed on  
5 probation, shall, as a condition of probation, satisfactorily attend and  
6 complete appropriate treatment and counseling on drug abuse provided by a  
7 program authorized under the Nebraska Behavioral Health Services Act or  
8 other licensed drug treatment facility.

9 (15) Any person convicted of violating this section, if sentenced to  
10 the Department of Correctional Services, shall attend appropriate  
11 treatment and counseling on drug abuse.

12 (16) Any person knowingly or intentionally possessing a firearm  
13 while in violation of subsection (1) of this section shall be punished by  
14 the next higher penalty classification than the penalty prescribed in  
15 subsection (2), (7), (8), (9), or (10) of this section, but in no event  
16 shall such person be punished by a penalty greater than a Class IB  
17 felony.

18 (17) A person knowingly or intentionally in possession of money used  
19 or intended to be used to facilitate a violation of subsection (1) of  
20 this section shall be guilty of a Class IV felony.

21 (18) In addition to the existing penalties available for a violation  
22 of subsection (1) of this section, including any criminal attempt or  
23 conspiracy to violate subsection (1) of this section, a sentencing court  
24 may order that any money, securities, negotiable instruments, firearms,  
25 conveyances, or electronic communication devices as defined in section  
26 28-833 or any equipment, components, peripherals, software, hardware, or  
27 accessories related to electronic communication devices be forfeited as a  
28 part of the sentence imposed if it finds by clear and convincing evidence  
29 adduced at a separate hearing in the same prosecution, following  
30 conviction for a violation of subsection (1) of this section, and  
31 conducted pursuant to section 28-1601, that any or all such property was

1 derived from, used, or intended to be used to facilitate a violation of  
2 subsection (1) of this section.

3 (19) In addition to the penalties provided in this section:

4 (a) If the person convicted or adjudicated of violating this section  
5 is eighteen years of age or younger and has one or more licenses or  
6 permits issued under the Motor Vehicle Operator's License Act:

7 (i) For the first offense, the court may, as a part of the judgment  
8 of conviction or adjudication, (A) impound any such licenses or permits  
9 for thirty days and (B) require such person to attend a drug education  
10 class;

11 (ii) For a second offense, the court may, as a part of the judgment  
12 of conviction or adjudication, (A) impound any such licenses or permits  
13 for ninety days and (B) require such person to complete no fewer than  
14 twenty and no more than forty hours of community service and to attend a  
15 drug education class; and

16 (iii) For a third or subsequent offense, the court may, as a part of  
17 the judgment of conviction or adjudication, (A) impound any such licenses  
18 or permits for twelve months and (B) require such person to complete no  
19 fewer than sixty hours of community service, to attend a drug education  
20 class, and to submit to a drug assessment by a licensed alcohol and drug  
21 counselor; and

22 (b) If the person convicted or adjudicated of violating this section  
23 is eighteen years of age or younger and does not have a permit or license  
24 issued under the Motor Vehicle Operator's License Act:

25 (i) For the first offense, the court may, as part of the judgment of  
26 conviction or adjudication, (A) prohibit such person from obtaining any  
27 permit or any license pursuant to the act for which such person would  
28 otherwise be eligible until thirty days after the date of such order and  
29 (B) require such person to attend a drug education class;

30 (ii) For a second offense, the court may, as part of the judgment of  
31 conviction or adjudication, (A) prohibit such person from obtaining any

1 permit or any license pursuant to the act for which such person would  
2 otherwise be eligible until ninety days after the date of such order and  
3 (B) require such person to complete no fewer than twenty hours and no  
4 more than forty hours of community service and to attend a drug education  
5 class; and

6 (iii) For a third or subsequent offense, the court may, as part of  
7 the judgment of conviction or adjudication, (A) prohibit such person from  
8 obtaining any permit or any license pursuant to the act for which such  
9 person would otherwise be eligible until twelve months after the date of  
10 such order and (B) require such person to complete no fewer than sixty  
11 hours of community service, to attend a drug education class, and to  
12 submit to a drug assessment by a licensed alcohol and drug counselor.

13 A copy of an abstract of the court's conviction or adjudication  
14 shall be transmitted to the Director of Motor Vehicles pursuant to  
15 sections 60-497.01 to 60-497.04 if a license or permit is impounded or a  
16 juvenile is prohibited from obtaining a license or permit under this  
17 subsection.

18 2. Renumber the remaining sections, correct internal references, and  
19 correct the operative date and repealer sections so that the sections  
20 added by this amendment become operative three calendar months after the  
21 adjournment of this legislative session.